The US Presidential elections have always represented a potentially pivotal moment for the global healthcare sector because of implications on drug pricing – and the recent elections have been no different.
Some investors are understandably concerned that the power to make legislative changes granted by the Democrats' clean sweep − gaining the Presidency, House of Representatives, and the Senate − could have negative implications for the healthcare sector. Biotech investors are more optimistic, with the caveat that in the short term there may be an element of headline risk. With the Democrats winning both of the Georgia run-offs in early January, each party now has 50 seats, and Vice President Kamala Harris will have the deciding vote, giving President Joe Biden the slimmest of majoritie...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
